James H. Stanker - 30 Sep 2022 Form 4/A - Amendment Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Chief Financial Officer
Signature
/s/ James H. Stanker by Michael B. Kirwan, as Attorney-in-Fact
Issuer symbol
PCSA
Transactions as of
30 Sep 2022
Net transactions value
$0
Form type
4/A - Amendment
Filing time
05 Oct 2022, 16:40:57 UTC
Date Of Original Report
03 Oct 2022
Previous filing
09 Aug 2022
Next filing
04 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCSA Restricted Stock Units Award $0 -12,950 -3.7% $0.000000 339,663 30 Sep 2022 Common Stock 12,950 $0.000000 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.
F2 Previous filing inadvertently underreported derivative securities beneficially owned by the reporting person.